Skip to content
Peptide Evidence Registry

Comparison Centre

Two compounds, the same questions, no cherry-picking

Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.

Sharing keeps the two compounds you picked.

How to read these scores

Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.

  • Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
  • Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
  • Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
  • Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
  • Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.

None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.

Oxytocin

The natural nonapeptide hormone of labour and lactation, long approved as an IV/IM obstetric medicine.

L5Repeated human trialsApproved medicine (jurisdiction-specific) · FDA (US)
Full profile

Carbetocin

A long-acting oxytocin analogue approved in many countries — but not the US — to prevent uterine atony after delivery.

L4Good human trialsApproved in some countries only · National authorisations (EU member states and other markets)
Full profile

How far human research has progressed

Oxytocin

Established obstetric medicine

Carbetocin

Approved regionally; long clinical use

Claim-specific benefit evidence

A human exposure study or trial registration does not establish that the claimed benefit occurs.

Oxytocin

Not separately assessed; see the full profile.

Carbetocin

Not separately assessed; see the full profile.

Human research context

Oxytocin

Established obstetric medicine

Carbetocin

Approved regionally; long clinical use

Human efficacy evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

Oxytocin

Strength of the human efficacy evidence85 of 100 evidence strength

Carbetocin

Strength of the human efficacy evidence70 of 100 evidence strength

Preclinical (animal / lab) evidence strength

Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.

Oxytocin

Strength of the animal and lab evidence80 of 100 evidence strength

Carbetocin

Strength of the animal and lab evidence70 of 100 evidence strength

Human safety evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

Oxytocin

Strength of the human safety evidence80 of 100 evidence strength

Carbetocin

Strength of the human safety evidence70 of 100 evidence strength

Regulatory status (legal position, not proof it works)

Oxytocin

Named regulators: FDA (US)

Approved (e.g. Pitocin) for specific obstetric indications including induction or augmentation of labour and control of postpartum bleeding, given by IV infusion or IM injection under medical supervision.

Carbetocin

Named regulators: National authorisations (EU member states and other markets)

Authorised in numerous countries through national approvals, including across EU member states via national procedures, for prevention of uterine atony and postpartum haemorrhage in specified obstetric settings. Not FDA-approved; EMA material describes nationally authorised products rather than a centralised EU approval.

Common claims

Oxytocin

  • · Induces or augments labour in defined obstetric situations
  • · Helps control postpartum bleeding
  • · Marketed online for mood, bonding and social effects via nasal sprays

Carbetocin

  • · Prevents uterine atony and excessive bleeding after caesarean delivery

How settled our evidence rating is

Oxytocin

High confidence in ratingL5Repeated human trials

Carbetocin

Moderate confidence in ratingL4Good human trials

Cancer-related questions raised by the biology

These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.

Oxytocin

No established human cancer signal within approved use.

Carbetocin

No established human cancer signal within approved use.

What this adds up to, in plain English

Oxytocin

Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.

Carbetocin

Real controlled human trials exist, but questions about approval, how long benefits last, or long-term safety are still open.

A comparison is not a recommendation

Neither column here is an endorsement, and the compound with the higher numbers is not the “better” or “safer” one — it is simply the one with more or better-quality research behind it. Two compounds can both be poorly evidenced, and better-evidenced says nothing about whether either is a sensible idea for a specific person. That is a conversation for a qualified clinician.